Why is having real-world data necessary to increase patient access and prove drug value? This was a common theme that ran throughout the recent Value-Based Strategies for Reimbursement and Formulary Success conference in Bethesda, Maryland sponsored by ExL Events, which drew pharmaceutical, specialty, and biotech professionals from across the country. The conference focused on market access and payer policies, and speakers from a number of industry giants addressed such issues as the importance of differentiating a product’s value from its therapeutic value; decreasing overall healthcare costs; proactive strategies that expand market access; and solving for the complexities HCPs face that delay patient therapy—especially in the oncology health model. Both public and private payers demand real-world data and modeling that demonstrates the up- and downsides of a product’s effect on all aspects of healthcare. ExL decided to merge this event with its Payer Partnership series beginning with a forum on June 11-12 in Boston.
Heather Thomson, MS, Associate Director, Medical Science, Director, Health Economics and Outcomes Research, kaléo, with Stephen A. Hull, Founder and Principle, Hull Associates LLC Market Access.Left to right: Terry McCurren, Senior Account Executive Market Access, Otsuka America Pharmaceutical, Inc. with Alexy Lara, Value, Access & Payment Director, Bristol-Myers Squibb.Natalie Berry, BSRT, RMC, Regional Account Manager, Mid America Region, Osiris Therapeutics, discusses payer challenges the pharmaceutical and biotech companies face in delivering high-quality treatment.Meeting sponsor, Stephen A. Hull, Founder and Principal, Hull Associates LLC, Market Access, greets attendees.Left to right: Raquel Cabo, Vice President, Global Market Access, Ovid Therapeutics; Jay Brown, Senior Director, Outpatient Pharmacy Services, Novant Health; Lawrence R. Nycum, MD, MMM, Senior Vice President, Novant Health; Melinda E. Hanisch, Director, Medical Policy & Quality Research, Center for Observational and Real-World Evidence, Merck; and Margaret Wong, Senior Director, Payer Contracting, Depomed.
